MGMT and glioblastoma: Two of these studies included or enrolled selectively newly diagnosed glioblastoma patients (designated as NCT03970447 and NCT06095375, respectively), in an attempt to evaluate multiple therapies in newly diagnosed glioblastoma (NCT03970447) or to obtain insights into regorafenib effectiveness in combination with temozolomide, with or without concomitant radiation, in newly diagnosed MGMT-methylated patients (NCT06095375).